X4 Pharmaceuticals Appoints Murray W. Stewart, M.D. to Board of Directors
“We’re very pleased to welcome Dr. Stewart to the X4 Board,” said
“X4 is at a critical juncture of growth and I am excited to join such a driven and dynamic team of leaders. As the company advances its pipeline of therapies for patients with rare genetic diseases and rare cancers, targeting the CXCR4 pathway, I look forward to contributing my experience and insights to help create long-term growth for a sustainable global rare disease business,” commented Dr. Stewart.
Dr. Stewart currently serves as Chief Medical Officer of
About
Forward-Looking Statements
This press release contains forward-looking statements that involve
substantial risks and uncertainties. All statements, other than
statement of historical facts, included in this press release regarding
our strategy, future operations, and plans are forward-looking
statements. Examples of such statements include, but are not limited to,
statements relating to plans for, or progress, scope, cost, duration or
results or timing for the initiation, completion or availability of
results of development of mavorixafor (X4P-001) or any of our other
product candidates or programs, including regarding the Phase 3 clinical
trial of mavorixafor for the treatment of patients with WHIM syndrome,
the target indication(s) for development, the size, design, population,
location, conduct, objective, duration or endpoints of any clinical
trial, or the timing for initiation or completion of or reporting of
results from any clinical trial, the potential benefits of mavorixafor,
or any other product candidate or program or the commercial opportunity
in any target indication; or the potential benefits of orphan drug
designation. Actual results or events could differ materially from the
plans, intentions, expectations and projections disclosed in the
forward-looking statements. Various important factors could cause actual
results or events to differ materially from the forward-looking
statements that X4 makes, including, but not limited to, the risk that
trials and studies may be delayed and may not have satisfactory
outcomes, potential adverse effects arising from the testing or use of
mavorixafor or other product candidates, the risk that costs required to
develop mavorixafor or other product candidates or to expand our
operations will be higher than anticipated and other risks described in
the “Risk Factors” section of the Registration Statement on Form S-4
filed by
View source version on businesswire.com: https://www.businesswire.com/news/home/20190402005267/en/
Source:
Investors:
Stephanie Carrington
Westwicke, an ICR
company
646-277-1282
Stephanie.Carrington@icrinc.com
Media:
Darcie Robinson
Westwicke, an ICR company
203-919-7905
Darcie.robinson@icrinc.com